Form 8-K - Current report:
SEC Accession No. 0001437749-25-022606
Filing Date
2025-07-11
Accepted
2025-07-11 17:27:35
Documents
17
Period of Report
2025-07-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20250711_8k.htm   iXBRL 8-K 32514
2 EXHIBIT 1.1 ex_838237.htm EX-1.1 200955
3 EXHIBIT 5.1 ex_838186.htm EX-5.1 11095
8 a01.jpg GRAPHIC 10221
9 arentfoxlogo.jpg GRAPHIC 10610
  Complete submission text file 0001437749-25-022606.txt   476065

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20250711.xsd EX-101.SCH 3579
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20250711_def.xml EX-101.DEF 11807
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20250711_lab.xml EX-101.LAB 15858
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20250711_pre.xml EX-101.PRE 12022
19 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20250711_8k_htm.xml XML 2946
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 251119786
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)